CD34 and non-Hodgkin lymphoma: YF-H-2015005, a biosimilar to plerixafor, has been found to increase the mean peripheral blood CD34+ cell counts by 2.0–2.9-fold and improve the quantity of mobilized CD34+ HSCs in peripheral blood with good tolerance, which can serve as a promising therapy for NHL patients undergoing AHSCT (13).